| Assessment Status | Rapid Review complete |
| HTA ID | 23035 |
| Drug | Vutrisiran |
| Brand | Amvuttra® |
| Indication | Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
| Assessment Process | |
| Rapid review commissioned | 06/07/2023 |
| Rapid review completed | 03/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that vutrisiran not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
